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comprehensive proteomic Analysis 
Reveals intermediate Stage of non-
Lesional psoriatic Skin and points 
out the importance of proteins 
outside this trend
edit Szél1, Renáta Bozó1, Éva Hunyadi-Gulyás  2, Máté Manczinger1,3, Kornélia Szabó1,3, 
Lajos Kemény  1,3, Zsuzsanna Bata-Csörgő1,3 & Gergely Groma1,3
to better understand the pathomechanism of psoriasis, a comparative proteomic analysis was 
performed with non-lesional and lesional skin from psoriasis patients and skin from healthy individuals. 
Strikingly, 79.9% of the proteins that were differentially expressed in lesional and healthy skin exhibited 
expression levels in non-lesional skin that were within twofold of the levels observed in healthy and 
lesional skin, suggesting that non-lesional skin represents an intermediate stage. proteins outside this 
trend were categorized into three groups: I. proteins in non-lesional skin exhibiting expression similar to 
lesional skin, which might be predisposing factors (i.e., CSE1L, GART, MYO18A and UGDH); II. proteins 
that were differentially expressed in non-lesional and lesional skin but not in healthy and lesional skin, 
which might be non-lesional characteristic alteration (i.e., CHCHD6, CHMP5, FLOT2, ITGA7, LEMD2, 
NOP56, PLVAP and RRAS); and III. proteins with contrasting differential expression in non-lesional and 
lesional skin compared to healthy skin, which might contribute to maintaining the non-lesional state 
(i.e., ITGA7, ITGA8, PLVAP, PSAPL1, SMARCA5 and XP32). Finally, proteins differentially expressed in 
lesions may indicate increased sensitivity to stimuli, peripheral nervous system alterations, furthermore 
MYBBP1A and PRKDC were identified as potential regulators of key pathomechanisms, including stress 
and immune response, proliferation and differentiation.
To date, all therapies available for psoriasis only manage symptoms. Understanding alterations that cause the 
disease is highly important for developing new therapies to better manage the disease.
Our skin connects, and at the same time separates internal the external environment. It is constantly subjected 
to many different stimuli that requires proper response, through which the skin can influences the function of 
other organs, like the brain and the endocrine system in a mutual way1,2. In psoriasis, the macroscopically healthy 
looking non-lesional skin harbors alterations that might cause symptoms3. One of the most characteristic prop-
erties of non-lesional skin is an altered response to mechanical stress or injury4 leading to barrier disruption5, 
which leads to an elevated innate immune response6,7. Alterations in non-lesional skin are not restricted to kerat-
inocytes. Angiogenesis is also among those mechanisms that is already affected in non-lesional skin, resulting 
in altered quantity and quality of microvessels8. In addition, it is becoming clear that some adaptive immune 
responses are also altered9. Abnormalities in the dermal extracellular matrix composition — such as elevated 
expression of the oncofetal splice variant of fibronectin10, due to altered splicing events11 indicate the involve-
ment of dermal fibroblasts3. Several matrix metalloproteinases (MMPs), such as MMP-9, previously thought 
to be increased only in lesions, are now known to be elevated in non-lesional skin compared to healthy skin12. 
There is also evidence for mechanisms in non-lesional skin that contribute to the maintenance of its state. The 
PRINS long non-coding RNA is induced by stress and nucleic acids, and it is anticipated to have a protective 
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function in psoriasis. PRINS in the non-lesional skin not only decreases inflammatory responses13 by inhibit-
ing IL-6 and CCL-5 mRNA translation, but also influences anti-apoptotic mechanisms14. Elevated expression of 
the anti-inflammatory regulator caspase recruitment domain family member 18 (CARD18) in non-lesional skin 
compared to healthy skin was found to aid the inhibition of inflammatory events15. These mechanisms, among 
many others, highlight the relevance of comparing non-lesional skin to healthy skin.
One of the most effective ways to study different diseases with such a high complexity and to elucidate 
related mechanisms is to perform a comparative proteomic analysis of protein extracts derived from affected 
tissues. Previous large-scale treatises including genomic, transcriptomic and proteomic studies have identified 
psoriasis-related markers playing key roles in the pathomechanism, such as AKR1B1016, CSTA17, FABP518, PI319, 
SCCA220, STAT116, STAT321, S100A718–20, S100A819,22 and S100A919,20,22,23, among others, thereby contributing 
greatly to the better understanding of the disease. However, none of the full scale proteomic studies17,18,22,24–27 
to the best of our knowledge, compared lesional and non-lesional psoriatic full thickness skin regions, with the 
inclusion of biopsies from healthy individuals as a reference in the comparison. The inclusion of healthy skin 
could provide several important additional information. I. Alterations that are similar in non-lesional and lesional 
skin, but differ from healthy skin, can be detected and used to identify potential novel disease markers or predis-
posing factors already present in the non-lesional skin. II. The comparison of non-lesional skin to healthy skin 
might facilitate the identification of inherent characteristics of psoriatic patients that are already present in their 
healthy-looking skin prior to lesion development. III. Information could be gained about the extent to which the 
non-lesional skin is affected in respect to lesional alterations. IV. Altered processes in the non-lesional skin that 
are contrary to the changes of lesional skin could be identified, some of which may contribute to the maintenance 
of the non-lesional state and serve as novel intervention points for disease management. We aimed to extend 
previous proteomic studies, in order to get more information regarding the putative alterations mentioned above. 
Therefore, a complex comparison was performed, where in addition to non-lesional and lesional skin, samples 
from healthy skin were also included, in a label-free, semi-quantitative proteomic analysis.
Results
Proteomic workflow and information on involved donors. Three biological replicas of our pro-
teomic approach were performed following sequential protein extraction of total skin biopsies. Each proteomic 
replica contained samples from three healthy donors as well as non-lesional and lesional biopsies from three 
psoriatic patients. The schematic overview of the applied proteomic strategy is summarized in Fig. 1 (also see 
Supplementary Information: Materials and Methods), and basic demographic and clinical characteristics of pso-
riatic patients and healthy donors are listed in Table 1. (Criteria for inclusion of patients in the study and skin 
sample collection are described at Supplementary Material: Materials and Methods section).
Biological processes associated with differential expression in healthy and lesional skin. As an 
initial step, proteomic results of lesional and healthy skin samples were compared and the relative abundance of 
249 proteins was found to be different (Fig. 2a and Supplementary Table 1). A protein–protein interaction-based 
enrichment analysis was performed with these proteins. We screened for interaction networks and biological 
processes related to the observed differences in expression using Gene Ontology (GO) analysis of the STRING 
database (version 10.5). Based on the GO nomenclature and protein composition, the identified biological pro-
cesses could be classified into the following categories: development, proliferation, regulation of expression and 
response to stimulus related processes. The ten most significantly different biological processes of each category 
are listed in Fig. 2b,c and Supplementary Table 2.
Since the major characteristics of psoriatic alterations include altered stress and immune responses as well as 
dysregulation of proliferation and differentiation, we screened among proteins expressed differentially in lesion 
compared to healthy skin for central regulators participating in all four of these mechanisms (Fig. 2d). As a result, 
four central proteins — MYBBP1A, PML, PRKDC and STAT1 — were identified (Fig. 2e).
Differential protein expression in non-lesional and lesional skin and the biological processes 
associated with these proteins. Comparison of non-lesional and lesional skin proteomes led to the iden-
tification of 56 proteins exhibiting at least 2-fold differences in relative abundances. Of these proteins, 32 exhib-
ited higher protein abundance in non-lesional skin compared to lesions, whereas 24 exhibited lower abundance 
(Fig. 3a and Supplementary Table 3). Functional enrichment analysis of these 56 proteins revealed several biolog-
ical processes identified in psoriasis pathomechanism, including development, and response to stimulus (Fig. 3b 
and Supplementary Table 4).
We also found a subset of proteins to be differentially expressed in non-lesional and lesional skin that were not 
differentially expressed in healthy skin and lesions (Fig. 3c).
The levels of eight proteins were greater in non-lesional skin and lower in lesional skin compared to the levels 
in healthy skin (non-lesional < healthy < lesional), and one protein exhibited the opposite trend (non-lesional > 
healthy > lesional). Although the non-lesional and lesional differences in the abundance of these proteins were 
not statistically significant when compared to healthy skin, the difference in abundance between non-lesional and 
lesional samples differed significantly by more than two-fold (Fig. 3d).
We also identified 44 proteins that had altered expression only in the comparison of lesional skin to either 
non-lesional or healthy skin; it is anticipated that these proteins play a role in manifestation and/or maintenance 
of lesions. The results of a computer-aided, keyword-based literature search suggests that, of these 44 proteins, 
23 are already associated with the disease (Fig. 3e), whereas 21 have not yet been associated with psoriasis patho-
genesis (Fig. 3f).
Proteins without previous association to psoriasis that exhibited decreased expression in lesions compared to 
expression in to both non-lesional and healthy skin include modulators of apoptosis, signaling, endothelial cell 
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proliferation, neurite outgrowth, migration, resistance to mechanical stress, cell–cell and extracellular matrix 
interactions, myelination of peripheral nerves, osmotic and membrane-potential regulation (Supplementary 
Table 5). In contrast, proteins with increased expression in lesions compared to both non-lesional and healthy 
skin are involved in cell death, cell proliferation, transcription and translation, calcium sensing (neuronal) and 
processing of class I MHC peptides (Supplementary Table 5). To further elucidate the significance in psoriasis 
of the differential expression of these latter three groups of proteins (Fig. 3c,d,f), a detailed automated literature 
analysis was conducted for associated known functions.
Comparison of protein expression in non-lesional skin compared to healthy skin. Proteins 
that were differentially expressed in non-lesional skin compared to healthy were also identified. Seven proteins 
exhibited higher expression levels in non-lesional skin compared to healthy skin and one with lower expression 
Figure 1. Schematic illustration of the applied proteomic workflow.
4Scientific RepoRtS |         (2019) 9:11382  | https://doi.org/10.1038/s41598-019-47774-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
(Fig. 4a). Among these, the relative amount of four proteins (GART, CSE1L, GBP1 and UGDH) was similar in the 
non-lesional and lesional skin samples. Out of the eight proteins that are differentially expressed in non-lesional 
skin compared to healthy GBP1, KLK10 and S100A7 have already been associated with psoriasis pathogenesis; 
the other five are potential novel, early markers of the disease.
To verify our proteomic results, immunofluorescent staining was performed to gain additional information 
regarding protein localization, deposition and distribution. UGDH had the largest expression differences in 
non-lesional and healthy skin. As UGDH has not been linked to psoriasis previously, this protein was chosen for 
further analysis. UGDH staining showed similar epidermal distribution in all three sample types, with the highest 
protein levels detected in basal keratinocytes (n = 10 different individuals in each group, listed in Supplementary 
Table 6). Despite the similarities in the UGDH localization pattern, clear differences in staining intensities were 
observed. The non-lesional and lesional psoriatic samples displayed more robust intensities compared to that of 
healthy samples, confirming our proteomic results (Fig. 4b,c).
To determine which lesional alterations and to what extent are manifest in non-lesional skin, we selected the 
249 proteins that exhibited differential expression in healthy and lesional skin and their expression levels was 
compared to those in non-lesional skin. In non-lesional skin, the expression of 199 (79.9%) of the proteins dif-
fered from the expression in healthy and lesional skin by less than two-fold. Therefore, this category was termed as 
intermediate, as they may represent a discrete step in the healthy-to-lesional transition (Supplementary Table 7).
psoriatic biomarkers, biological functions, canonical pathways and annotation of diseases 
associated with the detected alterations in protein amounts. To examine the validity of our exper-
imental approach, we further screened our proteomic dataset (lesional vs. healthy) for known, major biomarkers 
characteristic for psoriasis. These were identified previously in by large scale genomic, transcriptomic and/or 
proteomic studies. Out of these biomarkers AKR1B10, CSTA, FABP5, PI3, SCCA2, STAT1, STAT3 and members 
of the S100 family, including S100A7, S100A8, S100A9 were also found in our study. These molecules exhibited 
elevated expression levels in psoriatic lesions, compared to healthy control skin (Table 2).
Further analysis was performed to identify the cellular mechanisms that may be associated with the proteins 
that were detected in altered amounts in a proteomic approach, using the Ingenuity Pathway Analysis software 
(IPA). Diseases annotation revealed ‘psoriasis’ as the first hit when lesional and healthy (Table 3), or lesional and 
non-lesional differences (Table 3) were compared.
Annotation of biological functions by IPA highlighted ‘initiation of protein translation’ (Table 3) and ‘killing 
of Staphylococcus aureus’ as the main functions likely to be affected, respectively. Ingenuity canonical pathway 
screening identified the ‘role of IL-17A in psoriasis’ among the top ten most significant canonical pathways, when 
either lesional, or non-lesional protein expression was compared to healthy samples (Table 4). In addition, several 
cancer, neurological and neuromuscular canonical pathways were also highlighted.
Discussion
To expand knowledge about the pathomechanism of psoriasis, many extensive, large-scale comparative pro-
teomic approaches have been performed17,24,26. However, the comparison of healthy, non-lesional and lesional 
skin at the proteomic level has been missing from these studies. To fill this gap, our comparative proteomic anal-
ysis included healthy skin as well as non-lesional and lesional psoriatic samples.
Proteomic 
experiment
Group of 
donors Donors Age Gender
PASI 
score
No. 1.
Healthy
H I. 46
Male
n/aH II. 59
H III. 51
Plaque type 
psoriasis
P I. 65 17.1
P II. 63 9.9
P III. 50 5.5
No. 2.
Healthy
H IV. 23
Female
n/aH V. 48
H VI. 51
Plaque type 
psoriasis
P IV. 25 9.2
P V. 62 21.5
P VI. 70 17.5
No. 3.
Healthy
H VII. 37
Male
n/aH VIII. 39
H IX. 61
Plaque type 
psoriasis
P VII. 49 22.4
P VIII. 55 12.1
P IX. 61 12
Table 1. Basic demographic and clinical characteristics of donors involved in the proteomic analysis. (H: 
healthy donor, P: plaque-type psoriatic patient).
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Biological processes I.
Proliferation related processes Development related processes
Symbiosis, encompassing mutualism
through parasitism
Multi-organism process
Cellular component disassembly
Cell death
Keratinocyte differentiation
Epithelium development
Keratinization
Developmental process
Osteoblast differentiation
Extracellular matrix organization
Positive regulation of cell cycle arrest
DNA integrity checkpoint
Signal transduction by p53 class mediator
Mitotic cell cycle checkpoint
Negative regulation of 
ubiquitin-protein ligase activity
involved in mitotic cell cycle
Positive regulation of 
ubiquitin-protein ligase activity
involved in cell cycle transition
Cellular component assembly
Regulation of cell cycle phase transition
Negative regulation of cell cycle
Positive regulation of cell cycle arrest
b
c
Biological processes II.
Expression related processes Response to stimulus
Viral process
Innate immune
response
Antigen processing and presentation
of exogenous peptide antigen
via MHC class I
Defense response
Immune system process
Stimulatory C-type lectin receptor
signaling pathway
Cellular response to interleukin-4
Defense response to fungus
Regulation of defense response
Neutrophil aggregation
Translation
Nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay
mRNA metabolic process
Nuclear-transcribed mRNA
catabolic process
RNA processing
Ribonucleoprotein complex
biogenesis
RNA metabolic process
Posttranscriptional regulation of gene
expression
RNA splicing
Formation of translation preinitiation complex
4
Stress response
related proteins
Prolifera on
related proteins
Immune response
related proteins
Differen a on
related proteins
12  10 
15   2 
8
5  13 2  23 
3 11 
1 8
6 
Protein name Gene ID of protein Association with
psoriasis
Myb-Binding Protein 1A MYBBP1A novel
Protein PML PML known
DNA-Dependent Protein
Kinase Catalytic Subunit
PRKDC novel
Signal Transducer And
Activator Of Transcription 1
STAT1 known
d
e
Figure 2. Characterization of altered protein expression of lesional (L) skin compared to healthy (H) skin. 
Heatmap of relative expression of proteins differentially expressed in L and H skin (a, left column), and their 
expression in non-lesional (NL) and L skin (a, middle column) and NL and H skin (a, right column) (a). 
Biological processes for which proteins were differentially expressed in L and H are listed. The top ten processes 
are depicted for proliferation (b left, green circles), development (b right, blue circles), expression (c left, filled 
red circles) and response to stimulus (c right, orange circles). False detection rate (FDR) values are indicated 
with unfilled red circles around the filled circles for the various biological processes. The size of each circle 
is proportional to FDR values (unfilled circles) or to the number of proteins (filled circles). Four proteins 
differentially expressed in H and L skin are believed to participate in all four mechanisms of stress, immune 
response, proliferation and differentiation (d) and are listed in (e). (*Significant difference in relative protein 
expression at least by two-fold in L and H comparison).
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Protein name Gene ID ofprotein NL vs. L* L vs. H NL vs. H
Limma
(NL vs. L)
Rankprod
(NL vs. L)
Integrin alpha-7 ITGA7 2.983* 0.532 1.586 0.329 0.022
Plasmalemma vesicle-
associated protein PLVAP 2.284* 0.615 1.406 0.319 0.021
Cathepsin L2 CTSV¥ 2.431* 0.596 1.450 0.213 0.020
SWI/SNF-related matrix-
associated actin-dependent
regulator of chromatin
subfamily A member 5
SMARCA5 0.131* 1.768 0.232* 0.050 0.006
Collectin-12 COLEC12 2.842* 0.524 1.489 0.240 0.018
Skin-specific protein 32 XP32¥ 6.118* 0.262 1.601 0.010 0.005
Proactivator polypeptide-like 1 PSAPL1¥ 4.776* 0.300* 1.432 0.012 0.005
Integrin alpha-8 ITGA8 6.435* 0.222* 1.43 0.035 0.026
C-type lectin domain family 4
member K CD207
¥ 3.335* 0.387* 1.292 0.051 0.039
d
ABCA12 ITGA2 TOP1
AZU1 IVL TREX2
CD207 LCN2 XP32
CRABP2 LTF
DEFA1 MPO
EVPL NCAM1
FABP5 PI3
HMOX1 PSAPL1
HPSE S100A8
IL36G S100A9
Known psoriasis associated
trigger proteins 
Novel psoriasis associated 
trigger proteins
NCCRP1 ATP1B1 SYNM
RPL28 CNTN1
PRX MPZ
RPS11 VSNL1
ITGA8 RPL21
DDX21 PSME3
RPL23 SGCD
RPS15 MYH11
SLMAP RPS27
CSPG4 BCLAF1
e  f
Biological processes
Response to stimulus Development related processes
Multi-organism process
Symbiosis, encompassing mutualism through
parasitism
Cell-matrix adhesion
Epidermis development
Mesodermal cell differentiation
Cell adhesion
Extracellular matrix organization
System development
Tissue development
Formation of primary germ layerResponse to wounding
Innate immune response
Leukocyte migration
Chemotaxis
Sequestering of zinc ion
Response to stress
Neutrophil aggregation
Viral process
Immune system process
Defense response to fungus
b
c
Protein name Gene ID ofprotein NL vs. L* L vs. H NL vs. H
Limma
(NL vs. L)
Rankprod
(NL vs. L)
Protein function and
functional complexes
MICOS complex subunit
MIC25 CHCHD6 4.887* 0.248 1.213 0.281 0.014 MICOS complex
Charged multivesicular
body protein 5 CHMP5 0.293* 2.376 0.695 0.194 0.044 ESCRT-III complex
Collectin-12 COLEC12 2.842* 0.524 1.489 0.240 0.018 Scavenger receptor
Flotillin-2 FLOT2 2.043* 0.607 1.240 0.394 0.037 CSRM and CIE complex
Integrin alpha-7 ITGA7 2.983* 0.532 1.586 0.329 0.022 Cell surface receptor
LEM domain-containing
protein 2 LEMD2 2.163* 0.552 1.194 0.099 0.039
Nuclear lamina and
nuclear pore complexes 
Nucleolar protein 56 NOP56 0.390* 1.994 0.778 0.281 0.045 snoRNP complex
Plasmalemma vesicle-
associated protein PLVAP 2.285* 0.615 1.406 0.319 0.021 Endothelial diaphragm
Ras-related protein R-
Ras RRAS 2.293* 0.488 1.120 0.258 0.037 Lysosomal degradation
SWI/SNF-related matrix-
associated actin-
dependent regulator of
chromatin subfamily A
member 5
SMARCA5 0.131* 1.767 0.232* 0.050 0.006 Nucleosome remodelingfactor complex
Figure 3. Differential protein expression in lesional (L) and non-lesional (NL) skin and affected biological 
processes. Heatmap of relative expression for proteins differentially expressed in L and NL skin (a, left column) 
and the relative expression of these proteins NL and L skin (middle column) and L and healthy (H) skin (right 
column) (a). Biological processes for which proteins were differentially expressed in L and NL are listed. The 
top ten processes depicted to be affected in response to stimulus (b left, filled orange circles) and development 
(b right, filled blue circles). False detection rate (FDR) values are indicated with unfilled red circles around the 
filled circles for the various biological processes. The size of each circle is proportional to FDR values (unfilled 
red circles) or to the number of proteins (filled circles) (b). Proteins differentially expressed in L and NL but not 
in H and L are listed (c). Proteins for which the changes in NL and L compared to H are in different directions 
(increased vs. decreased and vice versa) are listed (d). Proteins that exhibited altered expression only in lesions 
(potentially trigger proteins) with known (e) and novel (f) association with psoriasis are listed. (*Significant 
difference in relative protein expression at least by two-fold in L and NL comparison).
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healthy non-lesional                         lesional
egre
M
IPAD
HDG
U
egre
M
HDG
U
b
c
a
Protein description Gene ID of protein NL vs. H* L vs. H NL vs. L
Limma    
(NL vs. H)
Rankprod 
(NL vs. H)
Trifunctional purine 
biosynthetic protein 
adenosine-3
GART 4.451* 4.325 1.029 0.389 0.047
Guanylate-binding 
protein 1 GBP1
¥ 5.925* 4.745* 1.249 0.161 0.046
Kallikrein-10 KLK10¥ 6.549* 20.793* 0.315 0.060 0.047
Exportin-2 CSE1L 7.204* 5.799 1.242 0.253 0.024
Protein S100-A7 S100A7¥ 7.519* 14.74* 0.510 0.027 0.024
Unconventional myosin-
XVIIIa MYO18A 8.191* 14.777* 0.554 0.027 0.024
UDP-glucose 6-
dehydrogenase UGDH 10.175* 8.269* 1.231 0.027 0.024
SWI/SNF-related matrix-
associated actin-
dependent regulator of 
chromatin subfamily A 
member 5
SMARCA5 0.232* 1.767 0.131* 0.050 0.006
Figure 4. Differentially expressed proteins in non-lesional (NL) and healthy (H) skin. Proteins with expression 
that differs by at least 2-fold in non-lesional skin and healthy skin are listed (a). UGDH protein expression 
is similarly increased in NL and lesional psoriatic skin, compared to H controls. The highest difference in 
expression for NL and H was seen with immunohistochemical characterization of UGDH (n = 10), which 
indicated similar patterns of distribution in the three sample types. The strongest staining was observed in basal 
keratinocytes, and weaker staining was observed in the upper parts of the epidermis. Higher intensity staining 
UGDH was observed in non-lesional and lesional skin compared to healthy skin (b). A higher magnification of 
the epidermis is provided (c). (In merged figures, DAPI nuclear staining and UGDH are shown in blue and red, 
respectively; *: indicates statistical significance, ¥: indicates proteins with known association with psoriasis).
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In order to check the validity of our proteomic approach we compared major known psoriatic biomarkers 
published in previous genetic (genome-wide association studies)21, transcriptomic19,21,23 and proteomic stud-
ies17,18,20,22 with our proteomic dataset. Known psoriatic lesional biomarkers also found in our study includes 
AKR1B1016, CSTA17, FABP518, PI319, SCCA220, STAT116, STAT321, S100A718–20, S100A819,22 and S100A919,20,22,23. 
Moreover, annotation of diseases resulted in the identification of psoriasis with the strongest correlation based 
on differentially expressed proteins in either lesional vs. healthy or in lesional vs. non-lesional comparison. 
Canonical pathway analysis of non-lesional differences compared to healthy skin resulted in the identification of 
‘Role of IL-17A in Psoriasis’. However, these annotations also highlighted cancer, neurological, neuromuscular 
or muscular disease-related mechanism, suggesting their potential involvement in disease pathomechanism, or 
some similarities between these diseases.
Since our proteomic and in silico analysis cannot distinguish between cell-types, and provide information 
whether mechanistically linked alterations are taking place within the same, or different cell types, further exper-
iments are required in this direction to clarify the exact relevance of these predicted connections to psoriasis 
pathomechanism.
We performed literature a search for known functions of proteins found to be altered in amounts in our study 
to suggest mechanism through which they may potentially participate in the pathomechanism of the disease. The 
detected differences in the expression of proteins in healthy and lesional skin highlighted involvement in psoriasis 
of cell proliferation28, development29, response to stimulus30, expression31 related processes. In the comparison 
of non-lesional and lesional skin, we identified 56 proteins with differential expression, which represents only 
22.5% of the number of proteins which showed altered expression in the comparison of healthy and lesional skin 
(56 vs. 249). This highlights the importance of studying healthy skin in comparisons using patient samples for 
pinpointing disease-associated alterations. Qualitative literature-based analysis of these 56 proteins led to the 
identification of several mechanism for which association with psoriasis has already been described, including 
processes related to development29, response to stimulus26 and expression31.
Further analysis focused on gaining insight about the extent to which alterations are manifest in lesions and 
in non-lesional skin. Strikingly, nearly 80% of the 249 proteins exhibiting differential expression in lesional and 
healthy skin exhibited an intermediate expression level in the non-lesional skin, suggesting the possible pres-
ence of early, lesional-like alterations in non-lesional skin. Divergence from this trend was only observed for 
two small protein groups. Ten proteins — CHCHD6, CHMP5, COLEC12, FLOT2, ITGA7, LEMD2, NOP56, 
PLVAP, RRAS and SMARCA5 — differed in relative protein amounts in non-lesional and lesional skin, but the 
amounts of these proteins were similar in healthy and lesional samples. These ten proteins are likely to represent 
a group of non-lesional characteristic alteration. For nine proteins — CD207, COLEC12, CTSV, ITGA7, ITGA8, 
PLVAP, PSAPL1, SMARCA5 and XP32 — the direction of the expressional changes was different in non-lesional 
and lesional samples compared to healthy skin and might represent proteins that contribute to maintaining the 
non-lesional state.
Next, with the proteins in these two groups, we performed an extensive literature search to suggest potential 
mechanisms by which they may influence disease pathogenesis. Interestingly, all the identified proteins may play 
a role in signaling at different levels starting from the cell surface all away to the nucleus or mitochondria. The 
identified cell surface receptors include two integrins (ITGA7 and ITGA8) that are important in external signal 
recognition. Decreased ITGA7 levels — as observed in lesional vs. non-lesional skin — could be associated with 
delayed autophagy32, differentiation33 and increased migration34, all known to be affected in psoriatic lesions. In 
contrast, elevation of ITGA7 may induce growth suppression35. However, ITGA7 is characteristically expressed 
mainly by smooth muscle cells36 in the skin, suggesting that its involvement in keratinocyte related events are 
at least limited, or none. Instead, may suggest alterations in (vascular) smooth muscle cell adhesion-related 
processes37. Alternatively, ITGA7 may influence neurite outgrowth38. Therefore, further studies are required 
to confirm the observed TGA7 expression alteration and to identify the cell-types of source. Another identi-
fied cell-surface molecule, MYO18A, through recognizing microorganism lipopolysaccharides, may increase 
innate immune responses39 promoting cytokine production towards Th1 direction40; known to be important in 
psoriasis41.
Gene ID of protein L vs. H NL vs. H NL vs. L
AKR1B10 32.769* 25.318 0.773
CSTA 2.335* 1.752 0.75
FABP5 15.076* 4.678 0.31*
PI3 52.616* 4.105 0.078
S100A2 5.878* 2.527 0.43
S100A7 14.74* 7.519 0.51
S100A8 20.639* 5.234 0.254*
S100A9 19.679* 3.306 0.168*
SCCA2 35.468* 9.221 0.26*
STAT1 20.504* 14.478 0.706
STAT3 3.766* 2.309 0.613
Table 2. Detected expressional differences of classic protein biomarkers for psoriasis.
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Categories (L vs. H)
Diseases or disease related 
processes p-value
Predicted 
Activation 
State Activation z-score
Number of 
Proteins
Disease annotation of protein expressional differences between lesional (L) and healthy (H) skin
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Psoriasis 6.89E-32 — — 61
Chronic psoriasis 2.15E-23 — — 27
Cancer, Cell Death and 
Survival, Organismal Injury and 
Abnormalities, Tumor Morphology
Cell death of osteosarcoma cells 4.04E-22 Decreased −4.899 24
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Chronic skin disorder 7.47E-22 — — 28
Cancer, Cell Death and 
Survival, Organismal Injury and 
Abnormalities, Tumor Morphology
Cell death of cancer cells 4.24E-15 Decreased −4.64 33
Infectious Diseases
Viral Infection 1.89E-12 Increased 3.883 69
Replication of virus 3.58E-11 — 1.819 34
Replication of RNA virus 1.93E-10 — 1.799 31
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Plaque psoriasis 4.05E-10 — — 15
Dermatological Diseases and 
Conditions, Immunological 
Disease, Inflammatory Disease, 
Organismal Injury and 
Abnormalities
Lichen planus 4.86E-10 — — 13
Categories (NL vs. L) Diseases or disease related processes p-value
Predicted 
Activation 
State
Activation z-score Number of Proteins
Disease annotation of protein expressional differences between non-lesional (NL) and lesional (L) skin
Dermatological Diseases and 
Conditions, Organismal Injury and 
Abnormalities
Psoriasis 3.72E-15 — — 21
Plaque psoriasis 1.78E-11 — — 10
Chronic skin disorder 3.06E-10 — — 10
Chronic psoriasis 8.58E-10 — — 9
Immunological Disease Allergy 8.57E-08 — — 12
Immunological Disease Hypersensitive reaction 1.30E-07 — — 12
Immunological Disease Immediate hypersensitivity 4.94E-07 — — 10
Dermatological Diseases and 
Conditions, Inflammatory 
Disease, Inflammatory Response, 
Organismal Injury and 
Abnormalities
Dermatitis 9.38E-07 — −1.067 11
Cardiovascular Disease, Organismal 
Injury and Abnormalities, Renal 
and Urological Disease
Ischemic acute renal failure 2.99E-06 — — 3
Organismal Injury and 
Abnormalities, Reproductive 
System Disease
Endometriosis 3.13E-06 — — 10
Categories (L vs.H) Biological Function p-value
Predicted 
Activation 
State
Activation z-score Number of Proteins
Biological function annotation of protein expressional differences between lesional (L) and healthy (H) skin
Protein Synthesis
Initiation of translation of 
protein 3.11E-46 — — 42
Translation 3.28E-40 — 0.737 57
Translation of protein 1.09E-38 — 0.555 55
Synthesis of protein 3.18E-36 Increased 2.691 64
Expression of protein 6.76E-36 — 0.527 57
RNA Damage and Repair Nonsense-mediated mRNA decay 3.06E-35 — — 32
Protein Synthesis Metabolism of protein 6.39E-31 Increased 2.92 85
Cell Death and Survival Necrosis 6.99E-18 Decreased −2.168 109
RNA Post-Transcriptional 
Modification Processing of RNA 4.39E-14 — −0.577 32
Cellular Movement Migration of cells 1.1E-12 Increased 2.067 83
Categories (NL vs. L) Biological Function p-value
Predicted 
Activation 
State
Activation z-score Number of Proteins
Continued
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FLOT242, CHMP543 and COLEC1244 participate in endocytic pathways, regulating the levels of cell-surface 
receptors and, thereby, signaling. FLOT2 is a known component of the raft microdomain complex that represents 
the major unit regulating STAT signaling pathways according to the raft-STAT signaling hypothesis45. The altera-
tion of FLOT2 expression could suggest a high relevance since STAT3 is a key regulator in psoriasis46. Reduction 
of the scavenger receptor COLEC12 could trigger psoriasis by trastuzumab treatment47. Moreover, COLEC12 
may influence the mitochondrial respiratory chain48, and this property is in agreement with the decreased level 
of mitochondrial MICOS complex subunit CHCHD649 observed in lesions compared to non-lesional skin. 
CHCHD6 regulates oxygen consumption and thereby may influence cell growth50. Reduced levels of CHCHD6 
were shown previously to lead to a shift from oxidative metabolism to glycolytic metabolism51 that negatively 
influences keratinocyte differentiation52, and both types of mechanisms are known to be affected in psoriasis53,54.
The altered expression of LEMD2 may suggest that signal transduction is also altered at the level of the 
nucleus. LEMD2, located in the inner nuclear membrane, regulates nuclear import/export processes55 and 
thereby intranuclear signaling50. During this regulation, LEMD2 is associated with the same complex as CHMP5, 
which was also identified in our studies. In the nucleus, the STAT-regulated protein NOP5656, a core protein of 
the box C/D small nucleolar ribonucleoprotein (snoRNP) complex, participates in the biogenesis of rRNAs57. 
Increased rRNA biogenesis is suggested to be necessary for high proliferation rate58, a process that is crucial for 
the development of psoriatic lesions.
Abnormal proliferation28, differentiation52 and, thereby, skin barrier function are key processes during pso-
riatic plaque formation. SMARCA5 is a component of the nucleosome remodeling factor complex59. Decreasing 
SMARCA5 levels are required for basal keratinocytes to shift form proliferation toward differentiation60. XP32 
is also a component of the epidermal differentiation complex61 and associated with skin barrier function62. The 
observed contrasting expressional differences of these two proteins in the non-lesional and lesional skin may 
contribute to our understanding of lesion formation and how non-lesional skin maintains its state.
Overall, our results indicate that dysregulation of cellular signaling — from signal detection, through endo-
cytosis of receptors and transduction of signal from the cell surface to the nucleus — may be affected during the 
disease. The alteration of these systems is likely to lead to increased reaction to external signals that could contrib-
ute to the maintenance of psoriatic plaques.
By comparing non-lesional and healthy skin, differential expression was observed for eight proteins (CSE1L, 
GART, GBP1, KLK10, MYO18A, S1007A, SMARCA5 and UGDH). Four of these proteins (CSE1L, GART, GBP1, 
UGDH) might be predisposing factors, as their expression was similar in non-lesional and lesional skin, and 
their significance would have been missed in comparisons for which healthy samples were not included. Of these, 
UGDH was detected with the highest relative difference. UGDH has not been highlighted previously in associ-
ation with psoriasis. We therefore decided to analyze it further. Immunohistochemical analysis confirmed our 
proteomic results: higher UGDH levels were found in non-lesional and lesional skin compared to healthy skin, 
that was mainly associated with keratinocytes. Elevated UGDH levels may increase chondrocytes proliferation 
indirectly, likely through increased hyaluronan production that binds different cytokines63. However, in vitro 
downregulation of UGDH and consequently decreased hyaluronan amounts did not influence keratinocyte pro-
liferation64. These results are in line with our observation, suggesting that elevated UGDH levels observed in 
non-lesional keratinocytes are not sufficient to modify their proliferation.
Categories (L vs. H)
Diseases or disease related 
processes p-value
Predicted 
Activation 
State Activation z-score
Number of 
Proteins
Biological function annotation of protein expressional differences between non-lesional (NL) and lesional (L) skin
Cell Death and Survival Killing of Staphylococcus aureus 8.53E-10 — −0.655 5
Cellular Movement,Immune Cell 
Trafficking Leukocyte migration 7.62E-08 — −0.509 18
Cell Death and Survival Killing of bacteria 1.10E-07 — −1.608 6
Cell-To-Cell Signaling and 
Interaction, Reproductive System 
Development and Function
Binding of gonadal cell lines 1.19E-07 — 1.964 6
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking
Cell movement of leukocytes 1.55E-07 — −0.429 16
Cell Death and Survival Necrosis 2.20E-07 — −1.927 30
Antimicrobial Response, 
Inflammatory Response Antimicrobial response 2.42E-07 Decreased −2 10
Cell Death and Survival Killing of Staphylococcus aureus subsp. aureus 5.03E-07 — — 3
Cellular Movement, Hematological 
System Development and 
Function, Immune Cell Trafficking, 
Inflammatory Response
Cell movement of phagocytes 5.87E-07 — −0.902 13
Cellular Compromise, 
Inflammatory Response Degranulation of cells 6.21E-07 — −0.87 13
Table 3. Disease and biological function annotation of differentially expressed proteins.
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Proteins for which expression was affected only in lesions are often considered “trigger” proteins, as changes 
in the expression of these proteins are linked to the shift of the disease state. The proteins that have not previously 
been associated with psoriasis were categorized into two groups. The first group of proteins might contribute to 
the mechanosensitivity of the tissue (SGCD65, SYNM66, MYH1167, ATP1B168). The second group functions within 
the nervous system (MPZ, PRX69, CSPG470, CNTN1 and ITGA871, ATP1B172), could suggest the involvement of 
the peripheral nerve system in psoriasis73.
Finally, we searched for potentially central proteins in disease pathogenesis participating in key mechanisms 
of psoriasis including regulation of stress and immune response, proliferation and differentiation. Some of the 
identified proteins, such as PML74 and STAT175, have already been linked to psoriasis. We also identified two 
proteins, PRKDC and MYBBP1A, which have not previously been highlighted in context with the disease. The 
PRKDC may plays a role in the detection and repair of breaks in double-stranded DNA76 and mediates the phos-
phorylation of c-MYC77 and p5378 suggesting a potentially important role in psoriasis. The suggested altered 
expression by our results of the transcription factor MYBBP1A may also be among the potentially important 
proteins in psoriasis implicated in the pathogenesis since it functions as a co-repressor of NF-κB that may regulate 
responses to stress and cytokines79.
Taken together, our comparative proteomic approach of healthy, non-lesional and lesional skin led to the 
identification of various proteins which may function in psoriasis pathogenesis, providing a strong base for 
future studies. Proteins exhibiting opposite expression changes in lesional and non-lesional samples compared 
to healthy skin may function in the maintenance of the non-lesional stage and may represent future targets for 
therapeutic purposes.
Ingenuity Canonical Pathways (L vs. H) −log (p-value)
EIF2 Signaling 3.69E + 01
Regulation of eIF4 and p70S6K Signaling 1.95E + 01
mTOR Signaling 1.16E + 01
FAT10 Signaling Pathway 4.22E + 00
tRNA Charging 4.01E + 00
Role of IL-17A in Psoriasis 3.32E + 00
RAN Signaling 2.96E + 00
Intrinsic Prothrombin Activation Pathway 2.80E + 00
Polyamine Regulation in Colon Cancer 2.62E + 00
Neuroprotective Role of THOP1 in Alzheimer’s 
Disease 2.56E + 00
Ingenuity Canonical Pathways (NL vs. L) −log(p-value)
Caveolar-mediated Endocytosis Signaling 8.77E + 00
Paxillin Signaling 5.79E + 00
EIF2 Signaling 5.35E + 00
Virus Entry via Endocytic Pathways 4.51E + 00
IL-8 Signaling 4.41E + 00
Integrin Signaling 4.31E + 00
Agrin Interactions at Neuromuscular Junction 4.11E + 00
Regulation of eIF4 and p70S6K Signaling 3.88E + 00
NF-κB Activation by Viruses 3.68E + 00
mTOR Signaling 3.35E + 00
Ingenuity Canonical Pathways (NL vs. H) −log(p-value)
UDP-D-xylose and UDP-D-glucuronate 
Biosynthesis 3.10E + 00
5-aminoimidazole Ribonucleotide 
Biosynthesis I 2.92E + 00
Tetrahydrofolate Salvage from 
5,10-methenyltetrahydrofolate 2.70E + 00
Purine Nucleotides De Novo Biosynthesis II 2.36E + 00
Role of IL-17A in Psoriasis 2.29E + 00
Colanic Acid Building Blocks Biosynthesis 2.25E + 00
RAN Signaling 2.17E + 00
Intrinsic Prothrombin Activation Pathway 1.79E + 00
SPINK1 Pancreatic Cancer Pathway 1.66E + 00
MSP-RON Signaling Pathway 1.54E + 00
Table 4. Canonical pathways predicted to be affected in psoriasis based on detected expressional differences of 
proteins.
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Materials and Methods
ethics. Skin biopsy collection from donors, the procedure of collection and all experimental protocols were 
approved by the Regional and Institutional Research Ethics Committee and by the Human Investigation Review 
Board of the University of Szeged (SOEDAFN-002, IF-562-5/2016 and IF-15056/2015; 157/2015; 3638 and 2799, 
3517), strictly following the guidelines and regulations of the Declaration of Helsinki. Prior to surgical interven-
tion and following a detailed description of the skin biopsy donation procedure, participants provided written 
informed consent. No donor under the age of 18 was included in our study.
criteria for inclusion of patients in the study and skin sample collection. To identify alterations 
that are general in chronic plaque psoriasis and keep the number of volunteers for skin biopsy collection to a 
minimum, for our proteomic approach, we randomly engaged individuals (I) of different age to minimize pos-
sible age-related differences; (II) with various Psoriasis Area Severity Index (PASI) scores between 5 and 25, 
since the score for an individual patient varies over time and with relapse; (III) of both genders to avoid possible 
gender-associated differences; and (IV) with both early and late onset. A total of 9 (3 × 3) patients suffering from 
chronic plaque psoriasis and the same number of healthy donors were involved in our study. The data of individ-
uals involved in the study are summarized in Table 1. All psoriatic patients had not received any kind of treatment 
for the condition for at least 6 months. The 6 mm skin punch biopsies containing the epidermis and the dermis 
were collected from an area of the upper-middle gluteal region that is not exposed to sunlight. Both lesional and 
non-lesional samples were collected from patients. Non-lesional samples were taken at least 7 cm from the edge 
of the lesion subjected for biopsy. The presence of psoriasis was clinically verified for all patients, and clinical as 
well as demographic data of the donors are presented in Table 1.
comprehensive and comparative proteomics of healthy, non-lesional and lesional skin. Sample 
preparation from skin biopsy and sequential protein extraction. Samples were cut with a razor blade. Skin proteins 
were extracted sequentially in four consecutive solubility-based extraction steps. Extraction buffers were used in 
increasing order of their solubilizing properties for a better separation of proteins. Samples were initially incubated 
in extraction buffer I. (0.15 M NaCl, 50 mM Tris-HCl, pH 7.4) for 24 h at 4 °C in the presence of protease inhibi-
tors. Protein extracts were then clarified by centrifugation and separated from the pellet. This step was repeated 
by resuspending the pellet in extraction buffer II, which contained 1 M NaCl, 25 mM EDTA, 50 mM Tris-HCl, pH 
7.4. Following extraction with 250 mM SDS-containing extraction buffer III (8 h at room temperature), guanidine 
hydrochloride containing extraction buffer IV (4 M GuHCl, 10 mM EDTA, 50 mM Tris-HCl, pH 7.4) was applied 
for 48 h at 4 °C. The same protein extracts of the three donors were pooled in each investigated group (healthy, 
non-lesional, lesional). Extraction procedure was carried out three times and each contained extracted proteins of 
three donors following the pooling of the samples which were than subjected for downstream proteomic analysis.
Protein identification by 2D LC-MSMS. A total 35 µg protein from each sample was applied for mass spectrom-
etry analysis. A modified filter-aided sample preparation method was used for tryptic digestion of the protein 
extracts80. High-pH reversed-phase chromatography was performed on a C18 column (Phenomenex, Kinetex 5 µ 
EVO C18 100 A, 2.1 × 100 mm; cat. no. 00D-4622-AN, flow rate: 150 µl/min). Forty-eight fractions were collected 
from 1 to 25 minutes (half minute/fraction) and 4-4 fractions were combined (1,13,24,37; 2,14,25,38 and so on) 
to get 12 final fractions. Each fraction was subjected to nano LC-MSMS analysis on an Orbitrap Elite hybrid mass 
spectrometer (Thermo) coupled with a Waters nanoAcquity UPLC system, using a gradient elution after trapping 
the samples onto the trap column. Data-dependent analyses were applied; the 20 most intense peaks were selected 
for ion-trap collision-induced dissociation after each survey scan measured in the Orbitrap. Proteome Discoverer 
(ver.: 1.3) was used to generate MS/MS peak-list files and our in-cloud ProteinProspector (ver.: 5.16.0) database 
search engine was used for protein identification against the human sequences from the UniProtKB.2015.12.14.
random.concat (149781/55820795 entries searched) database. Detailed protocols and applied counting for semi-
quantitative analysis is described as Supplementary Information.
Immunofluorescence staining of skin sections for UGDH. For immunofluorescence analysis, 5 µm sec-
tions of frozen embedded skin biopsies from psoriatic patients (non-lesional and lesional skin) and healthy indi-
viduals were used. After fixation and permeabilization (Foxp3 staining buffer set, fixation/permeabilization kit, 
Miltenyi Biotec, used according to the description of the manufacturer), samples were blocked in Tris-buffered 
saline (TBS) containing 1% bovine serum albumin (BSA) and 1% normal goat serum (NGS) for 1 h at room temper-
ature. Samples were incubated overnight at 4 °C in TBS with 1% NGS and primary antibodies against UGDH (rabbit 
polyclonal antibody, ab155005, Abcam), diluted to 1:100. Following washing in TBS, AF546 secondary antibodies 
(Goat anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 546, A-11035, Invitrogen), 
diluted in TBS containing 1% NGS to 1:500, were applied for 1 h at room temperature.
Literature search to identify novel psoriasis-associated proteins. To identify proteins not yet linked 
with the pathomechanism of psoriasis, literature mining was carried out using protein names or the encoding 
gene’s HUGO Gene Nomenclature Committee (HGNC) symbol(s), applying the following strategy: each protein 
or gene name was searched together with “psoriasis” as a keyword using the RISmed R package.
Statistical analysis. To compare protein abundance from healthy, lesional and non-lesional skin extracts, 
significant differences were determined based on relative peptide ion chromatograms and spectrum counting 
and evaluated using two different approaches: (1) modified t-test (limma) and (2) rank product test (as described 
by Schwämmle et al.81) following t-test. We considered a protein amount to be different between two samples if 
at least one of the three tests were significant (test <0.05) and the absolute fold change was at least two or higher.
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